E
Encysive Pharmaceuticals
Pulmonary arterial hypertension treatment development and commercialization
About Encysive Pharmaceuticals
Encysive Pharmaceuticals Inc., founded as Texas Biotechnology in 1989 and later acquired by Pfizer, was a biopharmaceutical company focused on developing and commercializing small molecule drugs for cardiovascular and inflammatory diseases. The company's main product was Thelin™ (sitaxsentan sodium), an oral, once-daily endothelin A receptor antagonist designed to treat pulmonary arterial hypertension (PAH). Thelin gained marketing approval in the European Union, Canada, and Australia. In the EU, it was indicated for improving exercise capacity in patients with WHO functional class III PAH.
Despite approvals abroad, Encysive faced significant challenges in the United States. The U.S. Food and Drug Administration (FDA) issued multiple approvable letters but did not grant full approval, citing the need for more substantial evidence of effectiveness and recommending an additional Phase III clinical trial. These regulatory hurdles, combined with a strategic review, led to a major restructuring in 2007, which included a 70% reduction of its U.S. workforce and a change in leadership, with George W. Cole replacing Dr. Bruce D. Given as President and CEO.
In February 2008, Pfizer announced its intention to acquire Encysive Pharmaceuticals for approximately $195 million. The acquisition was completed in June 2008, making Encysive a wholly-owned subsidiary of Pfizer. The deal allowed Pfizer to acquire the rights to Thelin and integrate it with its own PAH treatment, Revatio, strengthening its position in the cardio-respiratory market. However, in 2010, Pfizer voluntarily withdrew Thelin from the market due to concerns about liver toxicity. Before the acquisition, Encysive's pipeline also included Argatroban, approved for treating thrombosis, and other compounds in development for conditions like asthma and multiple sclerosis.
Source: Dealroom company dataAt a glance
- Founded
- 1989
- Headquarters
- Houston, United States
- Sector
- Health
News
Open roles
Encysive Pharmaceuticals in the Houston ecosystem
The Encysive Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
- HGHudson Capital Group
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Encysive Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Encysive Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

